Atlas Trials

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

Clinical trial NCT06712875 · RECRUITING

Trial details

NCT number
NCT06712875
Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Low Grade GliomaHigh Grade Glioma
Start date
2025-04-01
Primary completion
2028-12-01
Enrollment
27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.